Enliven Therapeutics, Inc. (ELVN)
After hours:
| Previous close | 20.99 |
| Open | 21.81 |
| Bid | 22.53 x 200 |
| Ask | 22.80 x 200 |
| Day's range | 21.34 - 23.00 |
| 52-week range | 9.80 - 26.00 |
| Volume | |
| Avg. volume | 279,045 |
| Market cap | 1.065B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.01 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.33 |
Barrons.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investors
Coliseum Capital increased its stake in boat maker MasterCraft. Insight Venture Partners sold shares of cybersecurity firm SentinelOne.
BenzingaEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program
Thursday, Enliven Therapeutics Inc (NASDAQ:ELVN) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs). ELVN-001 is a small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML. “We are excited to present the first look at the safety and clinical activity of
GlobeNewswireEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative MMR rate of 44% (4/9) by 12 weeks in response-evaluable patients who were previously treated with asciminib ELVN-001 was well tolerated with no ≥ Grade 3 treatment-related non-hematologic toxicities reported Company to host virtual event with Key Opinion Leaders at 8:00 AM ET Today BOULDER, Colo.
